Skip to main content

Table 1 Participant characteristics, gender-averaged absorbed dose estimates (μGy/MBq), and effective dose (μSv/MBq) for 64Cu by intravenous (IV) and oral administration

From: Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [64Cu]copper PET/CT

 

IV

Oral

ID (sex/age)

IV1 (M/61)a

IV2 (F/25)

IV3 (M/24)

IV4 (F/22)

O1 (F/39)

O2 (M/27)

BW/height (kg/cm)

76/178

75/175

94/186

68/160

54/168

77/181

Dose (MBq)

116.4

66.04

73.0

77.0

57.3

61.3

Target organ

 Liver

415.0

467.0

462.0

446.0

317.0

335.0

 Gallbladder

87.8

108.0

126.0

68.4

144.0

119.0

 Stomach

48.3

61.1

58.0

48.8

274.0

238.0

 Small Intestine

188.0

238.0

191.0

168.0

369.0

395.0

 RLI

225.0

88.7

181.0

213.0

925.0

600.0

 LLI

250.0

87.1

120.0

121.0

30.4

375.0

 Kidneys

137.0

128.0

133.0

132.0

66.0

72.6

 Pancreas

116.0

122.0

110.0

173.0

51.8

51.5

 Red Bone Marrow

36.2

34.0

35.5

32.5

27.0

24.4

Effective Dose

67.6

56.2

62.0

61.3

114.0

112.0

  1. Data for critical target organs and effective doses for all individuals are displayed; for full list of organs, see Supplemental Table 3
  2. Abbreviations: BW Body Weight, RLI Right Large Intestine, LLI Left Large Intestine
  3. aDynamic PET/CT scan and blood samples not obtained